This page is for clinic owners and marketing teams who produce website content, social media posts, or paid ads targeting patients in France. France has some of the tightest advertising standards in the EU — and since 2023, aesthetic medicine influencer marketing has been banned outright. Performance marketing tactics that work in Germany or the Netherlands will trigger enforcement action in France.
Who This Page Is For
If your clinic is in France, or if you are based elsewhere and running French-language advertising targeting patients in France, this guide applies. A common misconception among non-French clinics is that because they are not French-licensed, French professional rules cannot touch them. That is correct for CNOM (the physicians’ order) — but it is not correct for DGCCRF (consumer law enforcement) or for the 2023 influencer law. DGCCRF can investigate, publicise sanctions, and use digital requisitions against manifestly unlawful online content regardless of where the clinic is based.
This page is especially critical for any clinic involved in aesthetic medicine, cosmetic surgery, or injectable treatments — and for any clinic that uses creators, ambassadors, or affiliate marketers to reach French patients. Those categories face specific rules that go beyond general advertising caution.
France draws a structural line between objective patient information and commercial persuasion. The legal system permits clinics to communicate professional information — qualifications, facilities, care pathways, usual fee ranges, booking mechanics. What it prohibits is making medicine look like ordinary consumer commerce: outcome guarantees, patient testimonials, competitive price-cutting, paid search priority for named doctors, and social proof mechanics are all outside what the French framework allows for physician-linked communications.
Since 2023, that framework has a harder edge for aesthetic content. The loi influenceurs (Law n°2023-451) expressly prohibits influencer promotion of aesthetic medicine and aesthetic surgery acts — there is no compliant version of this format in France. Simultaneously, the Ministry of Economy established a dedicated enforcement brigade inside DGCCRF specifically targeting health and aesthetic sector violations. The direction of travel is clear: France is tightening, not loosening, its enforcement posture on digital health advertising.
The French Trigger Word List
These are the phrases most consistently flagged in French compliance reviews. Many of them are standard performance-marketing language in other sectors — in French medical advertising they are either prohibited or create immediate enforcement risk.
| What you wrote | Why it’s a problem | What to write instead |
|---|---|---|
| Résultats garantis | Guaranteed outcome claims are prohibited under both the Code de la Consommation (misleading commercial practice) and the Code de déontologie médicale. No medical procedure outcome can be guaranteed; the claim is factually false and legally actionable under consumer law whether the clinic is French or foreign. | Les résultats sont évalués individuellement lors de la consultation médicale |
| Sans risque / 100% sans douleur / 100% sûr | Absolute-safety or zero-risk claims are misleading under the Code de la Consommation and incompatible with the Code de déontologie’s requirement for objective, prudent communication. Every procedure carries risk; denying it is both factually wrong and unlawful in the French advertising framework. | Procédure réalisée dans le respect des standards médicaux actuels — risques et alternatives abordés lors de la consultation |
| Avant / après (in patient-acquisition advertising) | Before/after images are not a blanket statutory ban in France — but they are prohibited where they create a guaranteed-outcome impression. In practice, before/after images in acquisition advertising (paid social, landing pages, ads) almost invariably create that impression. The Code de déontologie Ordre des médecins guidance treats this category as extremely high risk. For aesthetic procedures, treat before/after creatives as presumptively non-compliant. | Pour comprendre ce que la procédure implique réalistement, consultez notre page d’information médicale: [lien] |
| Meilleure clinique / N°1 en France / Chirurgien le plus expérimenté | Comparative or superiority claims about other doctors or establishments are explicitly prohibited in the Code de déontologie Ordre des médecins commentary. This includes claims about price, waiting times, quality, volume of procedures, and any language that “glorifies operating conditions or results.” Without third-party verified evidence, these claims also violate consumer law. | Clinique spécialisée en [domaine clinique] — équipe de praticiens qualifiés [titres officiels exacts] |
| Réduction / Promotion / Offre spéciale (for medical acts) | Fee reductions used as competitive tools are expressly prohibited under Article 67 of the Code de déontologie. Promotional pricing for medical acts crosses from permitted fee information into prohibited commercialisation of medicine. “Consultation à -30% ce mois” or “pack rhinoplastie à €2,900” are squarely in the prohibited zone. | Nos honoraires habituels sont communiqués lors de la prise de rendez-vous / Tarifs disponibles sur demande |
| Témoignage patient / Avis vérifiés / ★★★★★ “incroyable résultat” | Patient testimonials, review quotes, thank-you stories, star ratings, and any form of patient praise are not acceptable in doctor-linked advertising under the Code de déontologie Ordre des médecins commentary (Article R.4127-19-1). This applies regardless of whether the testimonials are genuine or disclosed as patient accounts. | Pour en savoir plus sur notre approche médicale: [lien vers page d’information] |
| Botox® / Résultats en 48h / Filler garanti naturel | Botox is a prescription product — public advertising of prescription medicines is regulated under ANSM rules and the Code de la santé publique. Pairing a prescription product name with outcome claims or timeframes adds a consumer-law misleading-practices layer on top of the prescription-advertising restriction. | Traitement à la toxine botulique — évaluation médicale préalable requise. Informations disponibles en consultation. |
| Sponsorisé — Rhinoplastie [clinic name] ❤️ (influencer post) | Influencer promotion of aesthetic medicine or aesthetic surgery acts is prohibited in France under Law n°2023-451 Article 4. This is an absolute prohibition — not a compliance issue solvable with #sponsored or #publicité disclosures. Any creator, ambassador, or affiliate posting promotional content about an aesthetic act for a French audience is running an unlawful campaign regardless of the disclosure. | This format cannot be made compliant for aesthetic acts in France. Remove entirely. |
| Dr. [Name] — Meilleur spécialiste en France (paid ad) | Article R.4127-20 of the Code de déontologie requires the named doctor to actively prevent commercial use of their name and qualifications by any organisation. Additionally, Article 80 (Ordre des médecins commentary) prohibits paid or engineered priority digital ranking for named physicians — including Google Ads top placements for a named doctor’s profile. | Dr. [Name] — [Titre officiel exact], [qualification] — exerce à [lieu]. Domaines : [liste factuelle] |
| Clinique Budapest — Résultats européens, prix imbattables | A foreign clinic targeting French patients is subject to French consumer law (DGCCRF) even if it is not French-licensed. “Prix imbattables” is a comparative pricing claim (prohibited in physician-linked communications), and the combination of an implied French targeting with a non-French practitioner creates a transparency issue under misleading-practices law. CNOM cannot act — but DGCCRF can. | Clinique [nom] — services médicaux disponibles à [localisation]. Informations sur les soins disponibles sur notre site. |
5 Real-World Rewrites — Before & After
Each example reflects real French-language clinic advertising patterns. The rewrites reflect what the French legal framework actually permits — not a cautious interpretation, but the documented compliance standard.
Problems: guaranteed outcome claim (“résultats garantis”) is prohibited under Code de la Consommation and Code de déontologie; unverifiable superlative (“N°1 à Paris”) violates deontological standards on comparative/superiority claims; “consultation gratuite ce mois” is a promotional conversion mechanic which is risky under Art.67 (fee-cutting as competitive tool).
Why it’s lower risk: no outcome guarantee, no comparative claim, free consultation mechanic replaced with neutral appointment framing. Aligned with the French deontological standard of objective, patient-informative communication.
Problems: guaranteed timeline claim prohibited under consumer law and deontology; promotional price reduction (20% discount) is prohibited under Art.67 Code de déontologie; before/after images in this acquisition context create a guaranteed-outcome impression — prohibited; urgency booking CTA combined with pricing = multiple simultaneous violations.
Why it’s lower risk: no outcome claim, no promotional pricing, before/after removed, urgency removed. Consultation framing is neutral and patient-informative rather than conversion-optimised.
Problems: “sans douleur” + “garantis” = absolute-safety claim and outcome guarantee (both prohibited); “€349” promotional pricing = Art.67 violation; before/after stories = guaranteed-outcome impression prohibited; influencer/ambassador recommendation of an aesthetic act = ABSOLUTE BAN under Loi n°2023-451 Art.4. This single creative violates five distinct rules simultaneously.
Why it’s lower risk: prescription product referenced correctly without promotional framing; no outcome claims; no pricing promotion; no before/after; influencer layer removed entirely (the only compliant option for aesthetic acts in France).
Problems: patient testimonial with star rating prohibited under Code de déontologie (Art. R.4127-19-1); unverifiable superiority claim (“la meilleure clinique”); outcome guarantee (“résultats garantis ou remboursé”) violates both deontological standards and consumer law; using Dr. Martin’s name and results claim in this commercial context requires his active oversight per Art. R.4127-20.
Why it’s lower risk: testimonial removed; superiority claim replaced with factual credentials; outcome guarantee removed; doctor profile presented as regulated professional information rather than conversion-focused creative.
Problems: comparative pricing claim (“prix imbattables”, “-25%”) violates Art.67 deontology prohibition and consumer law; unverifiable superlative (“meilleures offres d’Europe”); testimonial-style claim (“500 patients satisfaits”); before/after images in acquisition advertising; promotional urgency pricing. CNOM has no jurisdiction here — but DGCCRF does, and can investigate under misleading commercial practices, issue digital requisitions, and publicise any sanction. Maximum exposure: €300,000 fine + 2 years’ imprisonment under consumer law.
Why it’s lower risk: no comparative pricing, no superlative, no testimonials, no before/after, no promotional pricing. Factual clinic identification with neutral invitation to book — the only format aligned with what French consumer law and deontological standards permit for a foreign clinic advertising into France.
High Risk: The Specific Formats That Trigger Enforcement
High Risk 01 — Influencer Promotion of Aesthetic Acts
Since 23 June 2023, influencer promotion of aesthetic medicine and aesthetic surgery acts is prohibited in France under Law n°2023-451, Article 4. This is an absolute legislative ban — not an advertising standards guideline, not a self-regulatory recommendation. No form of disclosure, #publicité tag, or contractual arrangement makes this format compliant. Any creator, ambassador, or affiliate who publishes promotional content about a rhinoplasty, filler, liposuction, or similar aesthetic act for a French audience is running an unlawful campaign. The Ministry of Economy’s 2026 guide includes influencer promotion of aesthetic acts in its maximum-exposure sanctions table: up to 2 years’ imprisonment and a €300,000 fine.
What this means in practice: If your current agency or social media strategy includes influencer campaigns for aesthetic services targeting France, that programme must be suspended immediately. It cannot be fixed with a disclosure amendment — it must be removed.
High Risk 02 — Before/After Images in Patient-Acquisition Advertising
France does not have a blanket statutory ban on before/after images (unlike Germany’s HWG §11). However, the Code de déontologie and Ordre des médecins guidance prohibit before/after images where they create a guaranteed-outcome impression. In the context of paid advertising and patient-acquisition campaigns — where the purpose of the before/after format is precisely to imply “this result could be yours” — this prohibition applies in practice to virtually all acquisition-context before/after use. For aesthetic procedures, treat before/after creatives as presumptively non-compliant in France.
High Risk 03 — Patient Testimonials and Social Proof Mechanics
The Ordre des médecins commentary on Article R.4127-19-1 expressly states that a doctor should not mention ratings, evaluations, comments, thanks or testimonials from patients or third parties in professional communications. This covers star ratings, review snippets, “patient stories,” “before I found this clinic” narratives, and user-generated endorsement content. In the French framework, this is one of the clearest hard lines — the guidance is specific and there is no “permitted testimonial” zone.
High Risk 04 — Promotional Pricing and Price-Reduction Mechanics
Article 67 of the Code de déontologie expressly prohibits fee reductions used as a means of competition. Flash sales, “summer discounts,” package deals, limited-time offers, and discount codes for medical or aesthetic procedures are all within this prohibition. Publishing a fee range in a neutral format (as the Ordre’s own guidance recommends) is permitted. Using that pricing as a promotional traffic-driving tool — or cutting fees to undercut competitors — is not. The distinction France draws is between transparent fee information (compliant) and price-promotion as a customer-capture technique (prohibited).
High Risk 05 — Paid Digital Ranking and SEO Tactics for Named Physicians
Article 80 of the Code de déontologie (as interpreted in the Ordre des médecins’ official internet guidance) prohibits physicians from obtaining paid or otherwise engineered priority digital referencing. The commentary is explicit that this prohibition extends across internet use generally — not just to medical directories. It includes: purchasing Google Ads top-placement for a named doctor’s profile; promotional hashtag strategies designed to capture prospective patients for a physician account; and directory “top listing” packages that artificially boost a named doctor’s visibility. For clinics with named physicians on staff, their digital presence must be managed as regulated professional information, not standard performance marketing.
High Risk 06 — “DGCCRF Can’t Reach Us Because We’re Not in France”
This is the most dangerous misunderstanding for foreign clinics advertising into France. CNOM (the physicians’ order) cannot sanction a non-French-licensed clinic — that part is correct. But DGCCRF operates under consumer law, and consumer law applies wherever the targeted consumer is located, not where the advertiser is based. A Hungarian, Romanian, or Polish clinic running French-language paid social ads targeting French patients is fully within DGCCRF’s jurisdiction for misleading commercial practices. DGCCRF can investigate, publicise its sanctions (creating reputational risk beyond the fine itself), use digital requisitions against unlawful online content, and refer cases to the prosecutor. Maximum exposure under consumer law: €300,000 fine and up to 2 years’ imprisonment.
Yellow Lights: Proceed Only After Review
Yellow Light 01 — Fee Disclosure
Publishing fee information is permitted and in fact recommended by the Ordre des médecins — practitioners in liberal practice should state their usual fee ranges and accepted payment methods. The compliance boundary is this: fee information communicated as a neutral patient-information element is acceptable; fees used as a promotional vehicle (flash sales, comparative pricing, urgency mechanics) are not. “Tarifs disponibles sur demande” or a factual fee range on a practice information page is lower risk. “Consultation from €X — book before [date]” used as a paid ad headline is not.
Yellow Light 02 — Doctor-Branded Social Media Accounts
A named physician maintaining a professional social media presence is not per se prohibited — but the content must be managed as professional information rather than conversion marketing. Educational content about conditions, clinical credentials, care pathways, and factual information about the practice are the compliant zone. The moment the account is used for procedure-specific promotion with outcome implications, booking CTAs, or patient testimonials, it enters the prohibited zone. Additionally, promotional hashtag strategies specifically designed to capture prospective patients violate Art.80 (paid/engineered priority referencing prohibition).
Yellow Light 03 — Educational Procedure Content
France permits educational content about procedures — clinical, balanced, no promotional intent. The compliance boundary is the moment educational content starts functioning as a conversion funnel: when it includes pricing, outcome promises, booking links with promotional framing, or is used as a retargeting audience for paid ads. A factual article explaining what rhinoplasty involves, with the consultation process described and no outcome guarantees, is in the lower-risk zone. That same content with a “see our results” CTA leading to before/after images is not.
Yellow Light 04 — Content Involving Injectables, Prescription Medicines, or Devices
Any clinic marketing campaign that references injectables (Botox, fillers by name), prescription products, or medical devices by brand or product name triggers a separate ANSM compliance track on top of the standard consumer-law and deontological review. ANSM has an independent enforcement role for health-product advertising. Do not assume that compliance with the general deontological and consumer-law framework is sufficient — these products require a separate specialist review. ANSM publishes advertising-related decisions and visa application calendars on its official site (ansm.sante.fr).
Yellow Light 05 — ARPP/JDP Self-Regulatory Complaints
The ARPP (Autorité de Régulation Professionnelle de la Publicité) and the Jury de Déontologie Publicitaire operate a complaint-based, non-binding self-regulatory framework. JDP opinions are not legally binding fines — but they are published publicly, with the advertiser named, and remain visible for three years. A founded JDP complaint creates reputational exposure that is faster-moving and more public than a formal DGCCRF investigation. For a clinic entering France, a JDP complaint can surface during the brand-building phase and undermine the authority and trust positioning that healthcare marketing depends on. Treat the ARPP/JDP framework as a practical compliance review criterion, not a harmless self-regulatory box.
The Cross-Border Trap: Hungarian or CEE Clinic Advertising Into France
A recurring scenario: a Hungarian, Polish, or Romanian aesthetic clinic runs a French-language paid social media campaign targeting French patients. The creative includes before/after photos, a testimonial from a French patient, a “summer promotion” price, and the clinic’s branded hashtag. A French influencer with 80,000 followers has also posted a sponsored aesthetic procedure review.
What actually happens under French law:
CNOM has no jurisdiction — the clinic has no French licence. That is the only good news. DGCCRF has full jurisdiction under consumer law for the misleading elements: the before/after images that create a guaranteed-outcome impression, the outcome guarantee implicit in the testimonial, the promotional pricing. DGCCRF can investigate, publicise the outcome, use digital requisitions to require Meta or Google to act on the content, and refer to the prosecutor. The influencer post is an absolute violation of Loi 2023-451 Art.4 — promotional content about an aesthetic act for a French audience is prohibited regardless of where the clinic or influencer is based. The influencer (if non-EU) also faces the legal-representative and insurance requirement under Art.9 of the same law.
Maximum exposure: €300,000 and 2 years’ imprisonment for the misleading consumer practices. Separate €300,000 / 2-year exposure for the influencer aesthetic promotion. Plus platform-level content removal, public DGCCRF sanctions publication, and ARPP/JDP reputational proceedings running in parallel.
What the same budget should look like instead: Clinic identification (name, location, official specialist qualifications), factual description of procedures available and the consultation process, fee ranges as neutral information, and a neutral appointment booking CTA. No before/after, no testimonials, no promotional pricing, no influencer layer for aesthetic acts.
The Legal Framework in Brief
The French framework operates in four layers. The Code de la Santé Publique and the physician deontology code incorporated within it (Articles R.4127-13, R.4127-19, R.4127-19-1, R.4127-20, and deontological Articles 67 and 80) set the rules for physician communications — objective, prudent, patient-informative, not used for commercial advantage, no commercialisation of medicine. These rules bind French-licensed practitioners and clinics that employ them directly.
Consumer law operates on a separate track and applies to any entity advertising to French consumers — including foreign clinics. The Code de la Consommation prohibits misleading commercial practices. DGCCRF enforces this with investigative powers, public sanction publication, and digital requisition authority. The maximum penalty for misleading commercial practices is 2 years’ imprisonment and a €300,000 fine (source: Ministry of Economy Guide de bonne conduite 2026).
Law n°2023-451 of 9 June 2023 (the loi influenceurs) adds a third layer specifically for creator and influencer marketing. Article 3 imports all existing health-advertising rules into the influencer context. Article 4 adds an absolute prohibition on influencer promotion of aesthetic acts and of products/services presented as substitutes for medical treatment. Article 9 requires non-EU influencers targeting France to appoint an EU legal representative and hold EU insurance coverage. Violations carry the same maximum exposure as misleading commercial practices.
A fourth layer applies when medicines or medical devices are involved: ANSM regulates pharmaceutical and device advertising independently, with maximum penalties reaching 7 years’ imprisonment and €750,000. Prescription products cannot be advertised publicly. Named injectables (Botox, fillers) require specialist ANSM-track review distinct from general clinic advertising compliance.
Legal disclaimer: This page is educational and informational only. It is not legal advice. The information reflects regulatory sources verified as of June 2026 and is subject to change. Clinics and marketing teams should seek qualified French legal or compliance counsel before making publishing decisions for French-market campaigns. MedicalServiceFinder.com is not liable for decisions taken on the basis of this content.
Note: Exact CNOM disciplinary monetary fine amounts could not be confirmed from primary sources — sanctions described as avertissement, blâme, interdiction temporaire d’exercer, and radiation. Consumer law penalty figures are sourced from the Ministry of Economy Guide de bonne conduite (2026). DGCCRF-specific enforcement cases against foreign clinics were sparse in publicly available official sources at time of writing.
